| Summary: | The endocannabinoid system has been shown to have a vast span of therapeutic applications due to its integral role in maintaining neurochemical homeostasis in the mammalian brain. A recently discovered endocannabinoid-degrading enzyme, alpha/beta hydrolase domain 6 enzyme (ABHD6), is an attractive new drug target and its inhibition can be applied to a number of disease pathologies including cancer, neurodegenerative disorders, and metabolic disorders. As it has only recently been discovered, little is known about ABHD6 and this has stunted the structure-based design of potent, specific inhibitors.
|
|---|
